Results 231 to 240 of about 19,645 (252)
Some of the next articles are maybe not open access.
GM1 Ganglioside in the Treatment of Parkinson's Diseasea
Annals of the New York Academy of Sciences, 1998ABSTRACT: Since the early 1980s, numerous studies have been reported by laboratories around the world documenting the beneficial effects of GM1 ganglioside treatment on the damaged dopamine system in various animal and in vitro models. Based on the strength of these data, the first clinical studies designed to assess the efficacy and safety of chronic
openaire +2 more sources
HIGH LEVELS OF GM1-GANGLIOSIDE AND GM1-GANGLIOSIDE β-GALACTOSIDASE IN THE PAROTID GLAND
Otolaryngologic Clinics of North America, 1999Nakisa Nowroozi +6 more
openaire +1 more source
latrogenic hyperlipidaemia with GM1 ganglioside
The Lancet, 1993JohnW. Roberts +4 more
openaire +1 more source
Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans
Journal of Neuroscience Research, 2012Gusheng Wu, Robert W Ledeen
exaly
Parenteral administration of GM1 ganglioside to presenile Alzheimer patients
Acta Neurologica Scandinavica, 1990C G Gottfries, Kaj Blennow, P Fredman
exaly
GM1 Ganglioside: In Vivo and In Vitro Trophic Actions on Central Neurotransmitter Systems
Journal of Neurochemistry, 1998Maria Hadjiconstantinou, Norton H Neff
exaly
Ganglioside GM1 Reduces Fetal Alcohol Effects in Rat Pups Exposed to Ethanol In Utero
Alcoholism: Clinical and Experimental Research, 1994Basalingappa L Hungund
exaly